What Next for Atricure Inc (NASDAQ:ATRC) Stock After Increase in Shorted Shares?

November 10, 2018 - By Duane Lopez

AtriCure, Inc. (NASDAQ:ATRC) Logo

Investors sentiment increased to 1.38 in 2018 Q2. Its up 0.60, from 0.78 in 2018Q1. It is positive, as 7 investors sold AtriCure, Inc. shares while 30 reduced holdings. 13 funds opened positions while 38 raised stakes. 28.28 million shares or 5.97% more from 26.69 million shares in 2018Q1 were reported.
Wasatch Advisors invested in 367,739 shares or 0.12% of the stock. Paradigm Cap Mgmt has invested 0.11% in AtriCure, Inc. (NASDAQ:ATRC). Ameriprise Fincl holds 109,861 shares. Capital Advisers Limited Liability has invested 0% in AtriCure, Inc. (NASDAQ:ATRC). Wellington Mgmt Gp Ltd Liability Partnership invested in 3.26 million shares or 0.02% of the stock. Keybank Natl Association Oh has invested 0% in AtriCure, Inc. (NASDAQ:ATRC). Emerald Advisers Pa accumulated 498,586 shares or 0.51% of the stock. Td Asset Mngmt Inc reported 64,600 shares stake. 63,800 were reported by Renaissance Techs Llc. Parametric Assoc Limited Liability Co stated it has 57,149 shares. 139,919 were reported by Public Employees Retirement Of Ohio. Goldman Sachs Group Inc holds 0% or 127,943 shares. Blackrock reported 0% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC). Schwab Charles Investment Mgmt, a California-based fund reported 170,250 shares. Voya Investment Mgmt Limited Liability Co has 0% invested in AtriCure, Inc. (NASDAQ:ATRC).

Since May 15, 2018, it had 0 insider buys, and 3 selling transactions for $265,730 activity. On Wednesday, August 15 Noznesky Justin J sold $121,280 worth of AtriCure, Inc. (NASDAQ:ATRC) or 4,000 shares.

The stock of Atricure Inc (NASDAQ:ATRC) registered an increase of 1.78% in short interest. ATRC’s total short interest was 2.10M shares in November as published by FINRA. Its up 1.78% from 2.06M shares, reported previously. With 152,500 shares average volume, it will take short sellers 14 days to cover their ATRC’s short positions. The short interest to Atricure Inc’s float is 6.89%.

The stock decreased 2.64% or $0.89 during the last trading session, reaching $32.76. About 151,497 shares traded. AtriCure, Inc. (NASDAQ:ATRC) has risen 68.55% since November 10, 2017 and is uptrending. It has outperformed by 52.93% the S&P500.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company has market cap of $1.26 billion. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It currently has negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Coverage

Among 3 analysts covering Atricure (NASDAQ:ATRC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Atricure had 5 analyst reports since June 18, 2018 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, October 9. The firm earned “Buy” rating on Monday, June 18 by Needham. The stock of AtriCure, Inc. (NASDAQ:ATRC) earned “Buy” rating by Needham on Wednesday, June 27. The stock of AtriCure, Inc. (NASDAQ:ATRC) has “Buy” rating given on Wednesday, June 27 by Canaccord Genuity. The firm has “Buy” rating given on Wednesday, June 27 by Stifel Nicolaus.

More news for AtriCure, Inc. (NASDAQ:ATRC) were recently published by: Businesswire.com, which released: “AtriCure to Present at the Piper Jaffray 30” on November 08, 2018. Seekingalpha.com‘s article titled: “AtriCure’s (ATRC) CEO Mike Carrel on Q3 2018 Results – Earnings Call Transcript” and published on November 03, 2018 is yet another important article.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.